U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22O8
Molecular Weight 414.4053
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PODOFILOX

SMILES

COC1=CC(=CC(OC)=C1OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](O)C4=CC5=C(OCO5)C=C24

InChI

InChIKey=YJGVMLPVUAXIQN-XVVDYKMHSA-N
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603 http://products.sanofi.ca/en/condyline.pdf

Podofilox ((abbreviated as PPT), otherwise known as podofilox) is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox 0.5% solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown, but is believed to exert its antimitotic effect by binding to tubulin, at a site close to but not identical to the binding site of colchicine; it is thought that this antimitotic effect causes necrosis of wart tissue, the observed clinical effect. In addition, podofilox is known to interfere with nucleoside transport, which may also contribute to its action. Adverse effects reported in less than 5% of the patients included pain with intercourse, insomnia, tingling, bleeding, tenderness, chafing, malodor, dizziness, scarring, vesicle formation, crusting edema, dryness/peeling, foreskin irretraction, hematuria, vomiting and ulceration.

Approval Year

1990
111
Targets

Targets

Primary TargetPharmacologyConditionPotency
Tubulin
69
Target ID: CHEMBL2095182
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
CONDYLOX

Approved Use

Podofilox Topical Solution 0.5% is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). Diagnosis Although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma (so-called Bowenoid papulosis) is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with Podofilox Topical Solution 0.5%.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (49.4%)
Pain (54.3%)
Itching (59.3%)
Bleeding (29.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (79.2%)
Pain (79.2%)
Itching (83.3%)
Bleeding (45.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (52.3%)
Pain (55.8%)
Itching (60.5%)
Bleeding (32.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (83.2%)
Pain (49.6%)
Itching (52.9%)
Bleeding (28.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (71.4%)
Pain (71.4%)
Itching (57.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (81.9%)
Pain (50.4%)
Itching (52.8%)
Bleeding (26.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (mild, 32.2%)
Pain (mild, 23.7%)
Itching (mild, 32.2%)
Bleeding (mild, 19.2%)
Inflammation (moderate, 30.4%)
Pain (moderate, 20.4%)
Itching (moderate, 16%)
Bleeding (moderate, 3%)
Inflammation (severe, 9.3%)
Pain (severe, 11.5%)
Itching (severe, 7.8%)
Bleeding (severe, 0.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Bleeding 29.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 49.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 54.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 59.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding 45.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 83.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding 32.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 52.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 55.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 60.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding 28.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 49.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 52.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 83.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 57.1%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding 26.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 50.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 52.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 81.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding mild, 19.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Pain mild, 23.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Inflammation mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Itching mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Itching moderate, 16%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Pain moderate, 20.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Bleeding moderate, 3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Inflammation moderate, 30.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Bleeding severe, 0.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Pain severe, 11.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Itching severe, 7.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Inflammation severe, 9.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
UGT1A1
246

CYP2C8
1057

CYP2E1
1060

CYP2A6
879
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2A6
911
 no
CYP2C8
1117
 no
CYP2D6
2546
 no
CYP2E1
1146
 no
CYP3A4
2633
 yes [IC50 1.1 uM]
CYP2C9
2497
 yes [IC50 4.6 uM]
MRP1
232
 yes
P-gp
1932
 yes
UGT1A1
303
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B1-00688
http://www.3bsc.com/index/pro_info.php?id=20900
3B Scientific (Wuhan) Corp
3B2-0462
http://www.3bsc.com/index/pro_info.php?id=19818
AA Blocks
AA003A9R
https://www.aablocks.com/goods/Goods/detail?id=AA003A9R
Aaron Chemicals
AR003B1J
http://www.aaronchem.com/518-28-5
abcr GmbH
AB167899
http://www.abcr.com/shop/en/AB167899
AbMole Bioscience
M3496
http://www.abmole.com/products/podophyllotoxin.html
Achemtek
0104-003876
http://www.achemtek.com/518-28-5
Acorn PharmaTech
ACN-035836
http://www.acornpharmatech.com/
Acros Organics
AC228410010
https://www.fishersci.com/shop/products/podophyllotoxin-95-acros-organics/AC228410010
Acros Organics
AC228411000
https://www.fishersci.com/shop/products/podophyllotoxin-95-acros-organics-1/AC228411000
AHH Chemical co.,ltd
API-1441
http://www.ahhchemical.com/product/API-1441.html
AHH Chemical co.,ltd
MT-58075
http://www.ahhchemical.com/product/MT-58075.html
AHH Chemical co.,ltd
NP-0421
http://www.ahhchemical.com/product/NP-0421.html
AK Scientific, Inc. (AKSCI)
70719
http://www.aksci.com/item_detail.php?cat=70719
Alfa Chemistry
125670-69-1
https://www.alfa-chemistry.com/cas_125670-69-1.htm
Alinda
ALBB-020906
http://alinda.ru/finechem_en_.html?i=ALBB-020906
Aurum Pharmatech LLC
W-5067
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5067
AvaChem Scientific
2680
http://www.avachem.com/productSearch.asp?2680
Axon MedChem
3368
https://www.axonmedchem.com/product/3368
BioChemPartner
BCP24085
http://www.biochempartner.com/518-28-5-BCP24085
BioSynth
P-6980
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/P-6980.html
BLD Pharm
BD41750
http://www.bldpharm.com/products/518-28-5.html
Boerchem
BC202956
http://www.boerchem.com/?product_34100.html
Capot Chemical
20017
http://www.capotchem.com/en/20017.htm
Capot Chemical
PubChem20017
http://www.capotchem.com/en/20017.htm
Chem Scene
CS-1185
http://www.chemscene.com/518-28-5.html
Chemenu
CM110307
http://www.chemenu.com/products/CM110307
ChemFaces
CFN99168
http://www.chemfaces.com/natural/Podophyllotoxin-CFN99168.html
ChemMol
30101274
http://www.chemmol.com/chemmol/30101274.html
ChemMol
44001388
http://www.chemmol.com/chemmol/44001388.html
ChemMol
99098085
http://www.chemmol.com/chemmol/99098085.html
Chemspace
CSSB00000743982
https://chem-space.com/CSSB00000743982
Clearsynth
CS-O-30735
https://www.clearsynth.com/en/CSO30735.html
CSNpharm
CSN16748
https://www.csnpharm.com/products/podophyllotoxin.html
DAOGE BIOPHARMA
DG21-11821
https://www.daogechem.com/product/518-28-5.html
DC Chemicals
DCG-007
http://www.dcchemicals.com//product_show-Podophyllotoxin.html
eNovation Chemicals
D512514
https://www.enovationchem.com/ProductDetails.asp?ProductID=D512514
Glentham Life Sciences
GE0412
http://www.glentham.com/products/product/GE0412/
Hairui
HR138842
http://www.hairuichem.com/en/product/518-28-5.html
Herbest Bio-Tech
HP200546
http://www.bjherbest.com/analytical-standard/lignans/podophyllotoxin-518-28-5.html
iChemical
EBD2184800
http://www.ichemical.com/products/518-28-5.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network
LN00178261
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00178261
Matrix Scientific
79670
https://www.matrixscientific.com/079670.html
mcule
MCULE-9617461427
https://mcule.com/MCULE-9617461427/
MedChem Express
HY-15552
https://www.medchemexpress.com/Podophyllotoxin.html
MuseChem
I003874
https://www.musechem.com/product/I003874.html
Oakwood
358381
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=162982&ExtHyperLink=1
OChem
12425
http://www.ocheminc.com/index.php?act=psearch&pid=518P285
Otava
12486930
https://search.otavachemicals.com/#!/search?query=12486930&type=code&base=dbb
Parchem
36299
http://www.parchem.com/chemical-supplier-distributor/podophyllotoxin-026299.aspx
R&D Chemicals
8646
http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=8165
Renno Tech
RL03911
http://www.rennotech.com/product_show.asp?id=4231
Sigma-Aldrich
73379_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/73379?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
858447_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/858447?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
P4405_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/p4405?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
TripleBond
CP0089
http://www.triplebond-canada.com/prod/1520/
VladaChem
VL262072-100MG
https://www.vladachem.com/product.php?products=518-28-5
Yuhao Chemical
JZ2488
http://www.chemyuhao.com/4354-76-1.html
PubMed

PubMed

TitleDatePubMed
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Imiquimod for the treatment of genital warts: a quantitative systematic review.
2001
Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
2001 Dec
A fast and simple GC MS method for lignan profiling in Anthriscus sylvestris and biosynthetically related Plant species.
2001 Dec
Podophyllin office therapy against condyloma should be abandoned.
2001 Dec
The treatment of anogenital warts at home.
2001 Feb 8-14
GATA-4 and serum response factor regulate transcription of the muscle-specific carnitine palmitoyltransferase I beta in rat heart.
2001 Jan 12
A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage.
2001 Jun
Management of anogenital warts (condylomata acuminata).
2001 Nov-Dec
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
2001 Oct
Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream.
2001 Sep-Oct
Facial molluscum: treatment with cryotherapy and podophyllotoxin.
2002 Apr
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
2002 Dec 15
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
2002 Feb
Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells.
2002 Jun 14
Deoxypodophyllotoxin; the cytotoxic and antiangiogenic component from Pulsatilla koreana.
2002 Mar
Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
2002 Mar
Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex.
2002 Mar 14
External genital warts: diagnosis, treatment, and prevention.
2002 Oct 15
Cytogenetic analysis of giant oocytes and zygotes to assess their relevance for the development of digynic triploidy.
2002 Sep
Transcription factor IID recruitment and Sp1 activation. Dual function of TAF1 in cyclin D1 transcription.
2003 Apr 11
Naphthalene analogues of lignans.
2003 Feb 7
[Bacteremia due to Capnocytophaga spp.: two cases].
2003 Mar
Patents

Patents

05463040
2
JP2002541233A
406
JP2007508039A
116
JP2009526755A
475
JP4701159B2
91
JP4758474B2
87
JPH03262488A
1
JPH0753553A
2
JPH08269041A
1
JPS62294609A
1

Sample Use Guides

In Vivo Use Guide
Apply twice daily morning and evening (every 12 hours), for 3 consecutive days, then withhold use for 4 consecutive days. This 1 week cycle of treatment may be repeated up to four times until there is no visible wart tissue. Podofilox 0.5% solution is applied to the warts with a cotton-tipped applicator supplied with the drug. The drug-dampened applicator should be touched to the wart to be treated, applying the minimum amount of solution necessary to cover the lesion. Treatment should be limited to less than 10 cm2 of wart tissue and to no more than 0.5 mL of the solution per day.
Route of Administration: Vaginal
In Vitro Use Guide
Unknown
Name Type Language
Podophyllotoxin
MART.   MI   WHO-DD  
Preferred Name English
PODOFILOX
HSDB   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
PODOPHYLLOTOXIN [EP MONOGRAPH]
Common Name English
NSC-24818
Code English
PODOFILOX [VANDF]
Common Name English
PODOFILOX [ORANGE BOOK]
Common Name English
Podophyllotoxin [WHO-DD]
Common Name English
PODOPHYLLOTOXIN [MI]
Common Name English
PODOPHYLLOTOXIN [MART.]
Common Name English
CONDYLOX
Brand Name English
PODOFILOX [HSDB]
Common Name English
FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE, 5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-, (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.ALPHA.))-
Common Name English
(5R,5AR,8AR,9R)-5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE
Common Name English
PODOFILOX [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000008732
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
NCI_THESAURUS C67421
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
WHO-ATC D06BB04
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
WHO-VATC QD06BB04
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
Code System Code Type Description
PUBCHEM
10607
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
HSDB
7238
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
EVMPD
SUB14925MIG
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
RXCUI
8463
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m8933
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL61
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
NSC
24818
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
CAS
518-28-5
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
FDA UNII
L36H50F353
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
NCI_THESAURUS
C29368
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
WIKIPEDIA
PODOPHYLLOTOXIN
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
DRUG CENTRAL
3481
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
SMS_ID
100000091097
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
CHEBI
50305
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
MESH
D011034
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
USAN
AA-10
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
ECHA (EC/EINECS)
208-250-4
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
EPA CompTox
DTXSID3045645
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
DRUG BANK
DB01179
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
DAILYMED
L36H50F353
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of PODOFILOX
PARENT (METABOLITE ACTIVE)
Structure of NEV-801
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966